Background The platelet-to-hemoglobin ratio (PHR) is a proposed prognostic marker in cardiovascular disease, but it has not been evaluated against a broad major adverse cardiovascular events (MACE) endpoint in a dedicated percutaneous coronary intervention (PCI) cohort, and whether it adequately summarizes its two comp...
Jeong Tae Byoun, Donghyeon Joo, Sungho Jo et al.· Frontiers in Cardiovascular...· 0 citations
This study evaluated whether ticagrelor use is associated with improved ischemic outcomes compared with clopidogrel in Korean patients with acute coronary syndrome undergoing percutaneous coronary intervention. We analyzed patient-level data from 1,199 patients (614 clopidogrel, 585 ticagrelor) enrolled in two prospect...
Donghyeon Joo, Jeong Tae Byoun, Sungho Jo et al.· Chonnam medical journal· 0 citations
Among patients at high risk for ischemic events 12 months after drug-eluting stent implantation, clopidogrel monotherapy was noninferior to extended DAPT with respect to net adverse clinical events at 24 months.
Seung-Jun Lee, Yong-Joon Lee, Kyounghoon Lee et al.· New England Journal of Medic...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.